What responsible medical promotion means in Jordan
Pharmaceutical promotion can support informed professional dialogue when it is accurate, appropriately directed and consistent with the product information approved by the regulator. In Jordan, those principles sit alongside specific rules about which medicines may be promoted, to whom and through which channels.
Start with the right audience
The Jordan Food and Drug Administration (JFDA) has stated that promotional materials for medicines should be directed to healthcare professionals under the applicable requirements. In its 12 August 2024 notice, the JFDA also emphasized that direct promotion of medicines to patients in healthcare and pharmaceutical institutions is prohibited, and highlighted restrictions for digital promotion of non-prescription medicines without prior approval.
Use approved and balanced product information
JFDA's notice states that promotion must not precede proper registration, diverge from the product's approved Summary of Product Characteristics (SmPC), or promote unapproved indications, including off-label use. For teams preparing professional materials, this makes version control and medical review central parts of good practice.
Make review part of the workflow
- Confirm the intended audience and channel before content is drafted.
- Check every product statement against the current approved product information.
- Keep references, approval status and review dates with the material.
- Escalate product-specific claims and any promotional asset requiring regulatory approval before use.
Official references
JFDA notice on medicine-promotion controls · 12 August 2024 ↗
JFDA instructions, including the 2016 Instructions for Regulating Drug Promotion ↗
